Invasive growth: a MET-driven genetic programme for cancer and stem cells
about
Activated Met signalling in the developing mouse heart leads to cardiac diseaseThe H19 non-coding RNA is essential for human tumor growthCancers of unknown primary origin: current perspectives and future therapeutic strategiesTargeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signalingAsef2 and Neurabin2 cooperatively regulate actin cytoskeletal organization and are involved in HGF-induced cell migrationTargeting the hepatocyte growth factor-cMET axis in cancer therapyTumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signallingGenetic targeting of the kinase activity of the Met receptor in cancer cellsDoes it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer?Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerMET deregulation in breast cancerThe role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agentsAntioxidant Mechanisms and ROS-Related MicroRNAs in Cancer Stem CellsTargeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signalingCombination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft modelEngineered variants of InlB with an additional leucine-rich repeat discriminate between physiologically relevant and packing contacts in crystal structures of the InlB:MET complexOckham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerPathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneumPrognostic significance of c-Met in breast cancer: a meta-analysis of 6010 casesFibroblast nemosis arrests growth and induces differentiation of human leukemia cellsStable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK CellsCan oncology recapitulate paleontology? Lessons from species extinctionsDegenerate wave and capacitive coupling increase human MSC invasion and proliferation while reducing cytotoxicity in an in vitro wound healing modelMelanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through METCrk adaptor protein-induced phosphorylation of Gab1 on tyrosine 307 via Src is important for organization of focal adhesions and enhanced cell migration.MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis.CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance.Four individually druggable MET hotspots mediate HGF-driven tumor progression.Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications.Functional blockade of α5β1 integrin induces scattering and genomic landscape remodeling of hepatic progenitor cells.Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cellsc-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancerSema3E/plexin-D1 mediated epithelial-to-mesenchymal transition in ovarian endometrioid cancer.Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells.Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasisActivating mutation in MET oncogene in familial colorectal cancer.E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas.
P2860
Q21136030-EEB09330-10F5-4EDA-8E7F-FFAB8CBC0FBBQ21144433-2D3C6A90-76BE-4EE7-900F-0424340C5666Q21245496-CDC331CB-9306-434F-AA14-55E798D4C8B7Q24296700-87F7BEAB-1B08-4233-933E-8CA2347C9D94Q24317786-47C303D2-D236-4226-888A-3C464029E5EEQ24606259-EC7E217D-596B-403F-9B6B-312A40DC94B6Q24629299-132AEBA4-2548-4F47-A1F8-7E8C139FEEB8Q24675200-944849FE-1F80-4FA5-81DE-52ACFA6D2B6FQ26741977-B4298BA4-882F-4DF4-8EC5-29EAF1C1D0ADQ26747276-66F4FDED-748D-487E-829F-B71D7D9454CCQ26772969-A7B76176-863C-4AD7-9377-662823E3B0BFQ26781054-C0C0E3E2-105B-4002-8B66-39DFFFFFFFF2Q26823903-C73FF77C-BE15-4D05-BF58-212A22E53FE9Q26853528-71460855-6587-4A69-800B-F93B4FCFE11DQ27011423-A98F37D0-438F-48D8-B3FF-51E962984490Q27302940-ECE4A5C9-1D97-462A-93FA-57255EA623E8Q27671505-E338E69A-1D24-4189-88DE-5B63ADF19F64Q28067777-505E5732-097E-44A5-968B-E2ABD5017F1DQ28073129-017995F6-AF68-4F4C-8D77-DC0C067582BFQ28087523-BB0AB8F7-6A80-4D8C-BB78-AFC0D8FC1F63Q28258147-610083B1-D559-4988-B92C-2EEEA728E760Q28553147-C7042AD8-96EE-4991-B1E8-B3A3AFA0C19EQ28607703-726BE7A8-304A-40E8-88BC-157672960E27Q28741379-D9BC4700-28FF-4583-A492-69E60F70AC1CQ29618139-BF96CDFA-C862-4807-91D2-458A06424999Q30157305-1BF2F153-3A66-4B1E-B14A-01A0E36D6805Q30157439-597D050E-DAE6-46B0-B392-39683D7B3F01Q30500172-6A0F0293-3C80-4330-94B3-D850AC4BA8B5Q30581656-054A8B91-2BA9-42E1-8C13-8B949E061F8CQ31099702-39F90F3A-4283-4D0D-AA2D-045BB2D2B12DQ33722764-959EFA91-4210-4144-869E-F1A0E2019AB6Q33766973-F24FA59A-98FE-4F0B-8920-74E8D15FB3F8Q33823715-C83AF9F2-CF08-4215-AEB3-F072C510644DQ33886974-2DCFD507-5112-4BE8-ADED-297B9D9DFEBEQ33894880-4FB8446E-E0A2-4688-9883-A02501C090E8Q33901521-87FEB4D6-E5CD-4CB6-B903-B68C353E86C7Q33945484-E2341A8D-4FAD-4F2F-A96A-72DBDBA9DEF7Q33947318-89C9B31E-E9FC-4363-8BCE-D8C9C9B26113Q34039577-DD332655-EABA-4F7C-A0C4-41446B2C1608Q34088774-982A3D45-7563-48DB-83A1-EF4C3EB10250
P2860
Invasive growth: a MET-driven genetic programme for cancer and stem cells
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Invasive growth: a MET-driven genetic programme for cancer and stem cells
@ast
Invasive growth: a MET-driven genetic programme for cancer and stem cells
@en
Invasive growth: a MET-driven genetic programme for cancer and stem cells
@nl
type
label
Invasive growth: a MET-driven genetic programme for cancer and stem cells
@ast
Invasive growth: a MET-driven genetic programme for cancer and stem cells
@en
Invasive growth: a MET-driven genetic programme for cancer and stem cells
@nl
prefLabel
Invasive growth: a MET-driven genetic programme for cancer and stem cells
@ast
Invasive growth: a MET-driven genetic programme for cancer and stem cells
@en
Invasive growth: a MET-driven genetic programme for cancer and stem cells
@nl
P3181
P356
P1476
Invasive growth: a MET-driven genetic programme for cancer and stem cells
@en
P2888
P304
P3181
P356
10.1038/NRC1912
P407
P577
2006-08-01T00:00:00Z
P5875
P6179
1017465939